Search Results
May 27, 2026, 18:18 ET U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting- DECNUPAZ marks AbbVie's first ADC approved for blood cancerNORTH
More news about: AbbVie
May 27, 2026, 16:31 ET Jetperch Introduces Joulescope JS320 Precision Energy Analyzer for Low-Power Embedded System Development
requirements.The JS320 introduces improved offset stability, reduced leakage current, Enwavify™ v2 technology for current range changes, a 24-bit ADC, wider internal digital processing, and a linear-phase analog path. These improvements are especially important for BLE devices, battery-powered IoT
More news about: Jetperch LLC
May 27, 2026, 09:19 ET GBI Biomanufacturing Appoints Chandra Kelley as Chief Business Officer
McCool, President of GBI Biomanufacturing. "Chandra brings the client and market insights needed to deepen the way we support our early-stage antibody and ADC projects. Her experience structuring integrated and phase-appropriate work packages for rapid early phase supply aligns exceptionally well with GBI's
More news about: GBI Biomanufacturing
May 27, 2026, 05:38 ET Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List
efficient treatment option for adult patients with NF1-PN.Furthermore, Henlius' HLX43, a potential best-in-class broad-spectrum anti-tumor PD-L1 ADC, will have its key subgroup progression-free survival (PFS) data in non-small cell lung cancer (NSCLC) presented for the first time in a Rapid Oral Presentation
More news about: Fosun
May 27, 2026, 05:27 ET 復星國際入選2026《財富》「最受讚賞中國公司榜單」
Series）成份股。多項國際評級與指數表現持續提升，體現了復星在ESG治理、信息披露、風險管理及可持續發展實踐方面的長期積累與穩健成效。復星堅持創新驅動與社會責任相融合，走出一條科創驅動責任引領的可持續發展之路。旗下健康產業秉承為更多患者帶來治癒希望的初心，圍繞臨床空白需求，深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域，積極拓展慢病及罕見病等領域，打造具有長期競爭力的產品管線與綜合解決方案。同時，持續夯實抗體、ADC、小分子、細胞治療等核心技術平台，並拓展核藥、小核酸等前沿技術。在罕見病領域，以復邁寧為例，2025年，由復星醫藥自主研發的1類新藥蘆沃美替尼片（復邁寧）於中國境內獲批兩項
More news about: 復星
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
Phase I, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody-drug conjugate (ADC) in patients with advanced solid tumors.
More news about: Hackensack Meridian John Theurer Cancer Center
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanismsAdcendo will sponsor the Phase 1b clinical trial and MSD
More news about: Adcendo
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanismsAdcendo will sponsor the Phase 1b clinical trial and MSD will provide pembrolizumab
More news about: Adcendo
May 26, 2026, 00:35 ET Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
May 22, 2026, 08:30 ET Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Multi-omic Biomarker Research and Real-World Evidence
Session: Gynecologic Cancer. Date/Time: Monday, June 1, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 275.Antibody drug conjugate (ADC) biomarker targets in endometrial cancer (EC): Molecular characterization and implications for therapeutic decision-making. (Abstract 5616) Session:
More news about: Caris Life Sciences
May 21, 2026, 23:30 ET Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
Nectin-4-targeting ADC independently developed by Mabwell based on its ADC development platform. Mabwell is currently conducting multiple clinical studies for several indications including urothelial carcinoma, cervical cancer, esophageal cancer and breast cancer. It is the world's first Nectin-4 ADC to enter
More news about: Mabwell
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-Biotech
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma - NORTH
More news about: AbbVie
May 21, 2026, 17:34 ET Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago,
More news about: Formosa Pharmaceuticals Inc.,
May 21, 2026, 17:05 ET Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into a new option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs. Whitehawk's ADC platform leverages CPT113 as the core linker-payload technology,
More news about: Whitehawk Therapeutics, Inc.
May 21, 2026, 17:00 ET New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
squamous cell carcinoma in ChinaDemonstrating breadth of ADC platform with updates from novel ADC programs:Results from the first Phase I study in China of BL-M14D1, a novel DLL3 directed ADC, in patients with locally advanced or metastatic small-cell lung cancer
More news about: SystImmune, Inc.
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
advanced dedifferentiated liposarcoma.LY4052031 (investigational ADC targeting Nectin-4): In an oral presentation, initial results will be shared from the Phase 1 NEXUS-01 study evaluating LY4052031, an ADC targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma.Kelonia
More news about: Eli Lilly and Company
May 21, 2026, 17:00 ET Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
Servier.us.About Emi-LeEmi-Le is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary auristatin-F HPA payload with controlled bystander effect. This candidate
More news about: Servier Pharmaceuticals
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
May 20, 2026, 08:00 ET Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the TD Cowen 7th Annual
More news about: Whitehawk Therapeutics, Inc.
May 19, 2026, 20:00 ET Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
including T cell engagers developed from our proprietary AnTenGager® platform; ATG-125, a B7-H3 x PD-L1 bispecific antibody-drug conjugate (ADC) designed to combine ADC and immuno-oncology mechanisms; and ATG-207, a globally first-in-class αCD3-TGF-β bifunctional fusion protein for T cell-driven autoimmune
More news about: Antengene Corporation Limited
May 19, 2026, 18:00 ET Ultra Maritime Secures New Contract to Strengthen Royal Australian Navy's Undersea Defence Capabilities
/PRNewswire/ -- Ultra Maritime Australia has been awarded a contract by the Australian Department of Defence to supply Acoustic Device Countermeasure (ADC) units in support of the Royal Australian Navy. This latest agreement reinforces a trusted partnership spanning more than a decade, during which Ultra
More news about: Ultra Maritime
May 18, 2026, 21:35 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform) and ImBiTDC (TDC Platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of
More news about: Nanjing Leads Biolabs Co., Ltd.
May 18, 2026, 08:33 ET Tanmiah Secures Double Win at Product of the Year 2026 Awards, Reinforcing Leadership in Innovation and Local Excellence
May 18, 2026 /PRNewswire/ -- Tanmiah Food Company ("Tanmiah"), through its subsidiary Agricultural Development Company (ADC), a leading provider of fresh and frozen poultry and value-added products, proudly announces a double victory at the prestigious Product of the Year
More news about: Tanmiah Food Company
May 18, 2026, 08:23 ET Tanmiah Secures Double Win at Product of the Year 2026 Awards, Reinforcing Leadership in Innovation and Local Excellence
May 18, 2026 /PRNewswire/ -- Tanmiah Food Company ("Tanmiah"), through its subsidiary Agricultural Development Company (ADC), a leading provider of fresh and frozen poultry and value-added products, proudly announces a double victory at the prestigious Product of the Year
More news about: Tanmiah Food Company